ICU Medical, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; unaudited. ICU Medical develops and sells infusion systems and consumables, and critical-care products. Results include the Smiths Medical business, acquired in January 2022. Comparisons are affected by eight additional Smiths Medical billing days in Q1 2023.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $568.6 million | $543.1 million |
| Gross profit / margin | $192.0 million / 33.8% | $168.8 million / 31.1% |
| Operating income (loss) | $9.4 million | $(42.2) million |
| Net loss / diluted loss per share | $(9.8) million / $(0.41) | $(38.1) million / $(1.61) |
| Operating cash flow | $41.2 million | $(1.3) million |
- Revenue increased 4.7%. By business unit, Consumables revenue was $236.1 million (down 1.7%), Infusion Systems $161.7 million (up 17.0%), and Vital Care $170.8 million (up 3.7%). Management cited growth in ambulatory and syringe pumps, critical care and temperature management, partly offset by foreign exchange and lower vascular access revenue. Constant-currency growth was 0.7%, 20.7% and 6.2%, respectively.
- Gross margin improved 2.7 percentage points. Management attributed the improvement mainly to prior-year inventory purchase-accounting costs, foreign exchange and lower freight costs.
- Operating expenses were $182.6 million versus $211.0 million. Restructuring, strategic transaction and integration costs declined to $11.0 million from $33.9 million; Q1 2023 included $2.7 million of restructuring and $8.3 million of integration costs.
- Net interest expense rose to $22.5 million from $13.1 million, primarily due to higher SOFR rates.
- Cash and short-term investments totaled $224.2 million at March 31. Current assets were $1.213 billion and current liabilities $462.2 million. Operating cash flow included the effect of $139.6 million of receivables sold under a new purchase program; proceeds were $138.8 million, with a $0.8 million loss. The company said $58.0 million remained to be collected on the purchaser’s behalf and was removed from the balance sheet.
- Long-term debt carrying value was $1.647 billion, including $35.1 million current; aggregate loan principal was approximately $1.670 billion. No revolving-facility borrowings were outstanding. The $500 million revolver remained available, subject to its terms. The company reported compliance with debt covenants.
Material changes and outlook
- Compared with Q1 2022, revenue and gross margin improved, operating results moved from a loss to income, and net loss narrowed. The comparison is not fully like-for-like because of Smiths Medical acquisition timing and purchase-accounting effects.
- Cash from operations improved, but the receivables purchase program materially influenced receivables and reported operating cash flow. Inventory increased $52.0 million from year-end, which management attributed primarily to safety-stock building.
- No specific revenue or earnings guidance was provided. Management believes cash, expected operating cash flows, the receivables program and accessible credit facilities are sufficient for cash requirements over the next 12 months. Planned 2023 capital expenditures and expected restructuring/integration and quality-compliance spending were not materially changed from the 2022 Form 10-K estimates; this filing does not provide those estimates.
- Key exposures include acquisition integration, inflation and supply-chain disruption, foreign exchange, customer ordering patterns, and higher interest rates. A 1% SOFR change was estimated to affect annual term-loan interest expense by approximately $16.7 million. Medline accounted for approximately 15% of revenue in both periods.
- Smiths Medical’s 2021 FDA Warning Letter remains relevant. The estimated field service corrective-action liability was $48.6 million at March 31, 2023; actual costs may differ depending on the work needed for regulatory clearance. Management reported no material changes to previously disclosed risk factors and stated disclosure controls were effective.
- Other notable items include a $0.7 million gain from remeasuring contingent earn-outs and a Smiths Medical earn-out fair value of $20.3 million. Routine legal proceedings were not expected by management to have a material adverse effect.
Most important facts for investors to verify
- Whether revenue growth and margin gains persist after adjusting for acquisition timing, foreign exchange and prior-year purchase-accounting effects.
- How much operating cash generation depends on receivables sales, and whether the purchase program remains available on acceptable terms.
- Debt repayment capacity, interest-rate exposure, covenant headroom and access to the undrawn revolver.
- The final cost and regulatory status of the Smiths Medical field service corrective action, and progress on acquisition integration.
- Whether elevated inventory converts to sales and cash without additional obsolescence, discounting or working-capital pressure.